Jan. 08 2026
Source Page: Avelumab with axitinib for untreated advanced renal cell carcinomaJan. 08 2026
Source Page: Avelumab with axitinib for untreated advanced renal cell carcinomaJan. 08 2026
Source Page: Avelumab with axitinib for untreated advanced renal cell carcinomaJan. 07 2026
Source Page: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaJan. 07 2026
Source Page: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaJan. 07 2026
Source Page: Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)Jan. 07 2026
Source Page: Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)Jan. 07 2026
Source Page: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaJan. 07 2026
Source Page: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaJan. 07 2026
Source Page: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia